Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482053 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00482053: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00482053 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00482053, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if double autologous then allogeneic hematopoietic cell transplant may offer an improved treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional transplantation regimen.
Interventions
- DRUG Rituximab
- DRUG Carmustine
- PROCEDURE Autologous hematopoietic stem cell transplantation (auto-HSCT)
- PROCEDURE Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
- PROCEDURE Total lymphoid irradiation (TLI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00482053
The ClinicalTrials.gov registry entry for NCT00482053 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT00482053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00482053 about?
NCT00482053 is a clinical study titled "Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT". The purpose of this study is to determine if double autologous then allogeneic hematopoietic cell transplant may offer an improved treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional transplantation regimen.
What is the current status of trial NCT00482053?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2006-10. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00482053?
The interventions under investigation include: Rituximab (DRUG), Carmustine (DRUG), Autologous hematopoietic stem cell transplantation (auto-HSCT) (PROCEDURE), Allogeneic hematopoietic stem cell transplantation (allo-HSCT) (PROCEDURE), Total lymphoid irradiation (TLI) (PROCEDURE).
Who is sponsoring clinical trial NCT00482053?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.